AVARUA, Cook Islands, Aug. 26, 2026 /PRNewswire/ — Avenue International (Cook Islands) Limited ("Avenue CI") extends its sincere condolences to all those affected by the 2026 Kumamoto Earthquake in Japan.

The earthquake has had a significant impact across the region, where relief operations remain ongoing. Avenue CI recognises the dedication and tireless efforts of all first responders, local authorities, humanitarian organisations, and volunteers working to support the affected communities.

In support of these ongoing efforts, Avenue CI has donated JPY 1,000,000 to the 2026 Kumamoto Earthquake Relief and Recovery Donation Funds. We hope that this contribution will provide support to those affected and contribute to the ongoing relief and reconstruction efforts in local communities.

Japan has long been an important market within the North Asian region we serve. Over the years, Avenue CI greatly values its long-standing relationships with clients and business partners across Japan. Avenue CI believes that supporting local communities during times of crisis is a fundamental part of responsible corporate citizenship.

Avenue CI stands in solidarity with the people of Kumamoto and Japan, offering its heartfelt wishes for a safe, swift, and steady recovery.

About Avenue International (Cook Islands) Limited

Avenue International (Cook Islands) Limited ("Avenue CI") is a licensed trustee company in the Cook Islands offering integrated trust and wealth management solutions. Regulated by the Cook Islands Financial Supervisory Commission ("FSC"), adhering to rigorous compliance and assuring due diligence, Avenue CI upholds the highest standards of legitimacy, integrity, transparency and credibility in its business operations and demonstrates accountability for the safety of client assets.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction

Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain…

Hex Trust Partners with IDA to Provide Institutional-grade Custody for Stablecoin Products

HONG KONG, April 9, 2025 /PRNewswire/ — Hex Trust, a leading digital…

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable…